ABCL

AbCellera Biologics Inc.

Investor Moves

NameValueActionChangePriceLast Price
Paul Tudor Jones IITudor Investment
$8M2.3M shares
AddQ1 2026
$2M
$3.60
$6.74
Ken GriffinCitadel Advisors
$7M1.9M shares
TrimQ1 2026
$1M
$3.60
$6.74
Steven CohenPoint72
$4M1.1M shares
AddQ1 2026
$671k
$3.60
$6.74
Jim SimonsRenaissance Technologies
$5M1.5M shares
TrimQ1 2026
$3M
$3.60
$6.74
Polen CapitalInvestor
$-350.6K
ExitQ1 2026
$351k
$3.60
$6.74
Ken GriffinCitadel Advisors
$176.1K
AddQ4 2025
$176k
$4.46
$6.74

Insider Trades

NameValueActionPriceLast Price
Montalbano John S.Director
$95k20k shares
BuyMay 14, 2026
$4.77
$6.74
Thermopylae Holdings Ltd.10 Percent Owner
$131k38k shares
BuyFeb 27, 2026
$3.44
$6.74
Thermopylae Holdings Ltd.10 Percent Owner
$580k177.5k shares
BuyFeb 26, 2026
$3.27
$6.74
Booth AndrewChief Financial Officer
$146k42.6k shares
BuyFeb 27, 2026
$3.42
$6.74
Montalbano John S.Director
$178k50k shares
BuyNov 26, 2025
$3.57
$6.74
Thermopylae Holdings Ltd.10 Percent Owner
$742k343.6k shares
BuyMar 11, 2025
$2.16
$6.74

News

zacks.comJAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapieszacks.comJun 18benzinga.comJazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaborationbenzinga.comJun 17zacks.comIs ABCELLERA BIOLG (ABCL) Outperforming Other Medical Stocks This Year?zacks.comJun 17reuters.comJazz Pharma, AbCellera ink antibody deal worth up to $876 millionreuters.comJun 17prnewswire.comJazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodiesprnewswire.comJun 17